A phase 3 study found that bedtime sublingual cyclobenzaprine (TNX-102 SL), an investigational drug being developed by Tonix Pharmaceuticals Holding Corp, is well-tolerated and showed nominal improvement in post-traumatic stress disorder (PTSD) severity and sleep quality measures … [Read more...]